SCHEMBL10043876

SCHEMBL10043876

Cc1cc2c(cn1)cc(-c1cc(NC(=O)NC(=O)c3cccs3)ccc1C)c(=O)n2C

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.42
MAPT P10636 4/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 3/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
NPC1 O15118 9/20 0.41
SYK P43405 1/20 0.41
HSD17B10 Q99714 1/20 0.40
RXFP1 Q9HBX9 1/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PDE5A O76074 1/20 0.38
MAPK14 Q16539 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043708 0.93 RAB9A (0.48) RAB9AMAPTKDM4EALDH1A1HPGD
SCHEMBL10043838 0.87 GAA (0.47) RAB9AMAPTKDM4EALDH1A1KMT2A
SCHEMBL10043850 0.86 SYK (0.50) RAB9AMAPTALDH1A1HPGDKMT2A
SCHEMBL10043864 0.85 SYK (0.44) RAB9AMAPTKMT2AMEN1NPC1
SCHEMBL10043857 0.85 POLB (0.45) RAB9AMAPTALDH1A1KMT2AMEN1
SCHEMBL10043853 0.83 SYK (0.48) RAB9AMAPTKDM4EALDH1A1HPGD
SCHEMBL10043854 0.83 KDR (0.45) SYKLMNA
SCHEMBL10043877 0.83 RAB9A (0.45) RAB9AMAPTKDM4EALDH1A1HPGD
SCHEMBL10043860 0.83 SYK (0.51) RAB9ANPC1SYKMAPK14
SCHEMBL10043821 0.82 SYK (0.49) RAB9AMAPTKMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAB9A 1818/4885MAPT 2514/4885KDM4E 1572/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAB9A 1818/4885MAPT 2514/4885KDM4E 1572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.